Drug intelligence / Profile preview

AOC-024

Development stage: Preclinical
Lead developer: iProgen Biotech
Modality: Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AOC-024 is an antibody-oligonucleotide conjugate (AOC) currently in the discovery phase for the treatment of oncology. Developed by iProgen Biotech in partnership with Biorchestra, the therapeutic candidate utilizes iProgen's antibody-based delivery platform to transport Biorchestra's proprietary oligonucleotide payloads specifically to cancer cells. This approach aims to combine the high specificity of monoclonal antibodies with the gene-modulating capabilities of RNA-based therapies to improve therapeutic outcomes in cancer patients.

Beyond the preview

Go deeper on AOC-024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AOC-024.

Explore the full profile